Autosomal Recessive Spastic Paraplegia Type 69 (SPG69)

Autosomal recessive spastic paraplegia type 69 (SPG69) is a rare, inherited neurological disease in the hereditary spastic paraplegia (HSP) family. HSPs are disorders where the main problem is stiffness (spasticity) and weakness in the legs due to damage of the long motor pathways (corticospinal tracts). In SPG69, symptoms typically begin in infancy, and the condition is usually “complex” HSP, meaning the leg problems are joined by other issues such as developmental delay, speech difficulties, learning problems, cataracts, hearing loss, and structural brain findings on MRI. The disease follows an autosomal recessive inheritance pattern: a child must receive a faulty copy of the same gene from both biological parents to be affected. rarediseases.info.nih.gov+1

SPG69 is a rare, inherited nerve disorder in the large group called hereditary spastic paraplegias (HSPs). In SPG69, the long nerve fibers that carry movement signals to your legs slowly become weak and stiff (spastic). Symptoms usually include tight, stiff leg muscles, trouble walking, falls, and fatigue; some families can also have eye, learning, or other “complicated” features. It follows an autosomal recessive pattern, which means a person gets one non-working copy of the gene from each parent. SPG69 is linked to changes (variants) in the RAB3GAP2 gene, which is involved in the cell machinery that moves tiny packets (vesicles) inside nerve cells; RAB3GAP2 is also known in some catalogs by the alias SPG69. Overlap with syndromes like Martsolf/Warburg micro has been reported, which helps explain variable features. Diagnosis relies on clinical signs plus genetic testing. There is no single cure; care focuses on spasticity control, safety, mobility, bladder and bowel care, mood, and quality of life. Wikipedia+2Cleveland Clinic+2

Another names

• SPG69 (short form used in HSP lists and clinics) rarediseases.info.nih.gov

• RAB3GAP2-related HSP (describes the causal gene) orpha.net+1

• Sometimes described within the Warburg micro/Martsolf spectrum, because the same gene can also cause these overlapping syndromes; SPG69 represents the HSP presentation within that spectrum. National Organization for Rare Disorders+2PubMed+2

SPG69 is caused by biallelic (two-copy) pathogenic variants in the gene RAB3GAP2 on chromosome 1q41. RAB3GAP2 encodes the non-catalytic (regulatory) subunit of the RAB3GAP complex, which helps regulate small GTPase proteins (notably RAB3 and RAB18) that control how nerve cells move and release vesicles and build/maintain long axons. When RAB3GAP2 is not working, the molecular traffic inside neurons is disturbed, which contributes to axon dysfunction and spasticity. Wikipedia+2ensembl.org+2

In simple words: the RAB3GAP2 gene is part of a two-protein team that times “traffic lights” for packets inside nerve cells. If that timing fails in both gene copies, long motor nerve fibers get sick over time, causing leg stiffness and other features.

Types

HSPs are traditionally split into:

• “Pure” HSP – mainly leg spasticity/weakness.

• “Complex” HSP – leg spasticity plus other neurological or systemic features.

SPG69 is a complex HSP, usually with early (infant) onset and additional features like developmental delay, cataracts, hearing loss, and characteristic MRI findings. rarediseases.info.nih.gov+1

---

Causes

Because SPG69 is monogenic, the true cause is pathogenic variants in RAB3GAP2. The list below breaks “causes” into (a) variant types that damage the gene and (b) biological mechanisms through which the gene defect harms the nervous system, plus (c) modifiers that can influence severity. This is the most accurate way to give 20 well-explained “causes” for a one-gene disease.

1. Loss-of-function (LoF) variants (e.g., nonsense, frameshift) that truncate RAB3GAP2 and abolish normal protein function. PubMed+1

2. Missense variants that change one amino acid and disrupt the protein’s binding to its partner RAB3GAP1 or to RAB3/RAB18 pathways. UniProt

3. Splice-site variants that mis-process the RNA and yield abnormal protein. (Splice variants in RAB3GAP2 have been reported.) University of Chicago Genetic Services

4. Small deletions/insertions that shift the reading frame and inactivate the protein. PubMed

5. Larger deletions/duplications (CNVs) removing key exons or the whole gene. (Detected on exome/CNV panels.) Eurofins Biomnis Connect

6. Failure of the RAB3GAP complex assembly when mutant RAB3GAP2 cannot partner properly with RAB3GAP1. UniProt

7. Disrupted RAB3 cycling (overactive or poorly inactivated RAB3), leading to abnormal synaptic vesicle exocytosis at nerve terminals. UniProt

8. Disrupted RAB18 regulation (RAB3GAP complex also serves as a GEF for RAB18), altering ER–Golgi dynamics and lipid trafficking important for axons. UniProt

9. Axonopathy of long corticospinal tracts—long motor fibers are especially vulnerable to traffic defects. (General HSP mechanism.) PMC

10. Abnormal myelination seen in some complex HSPs/ SPG69, which may amplify conduction problems. rarediseases.info.nih.gov

11. Developmental brain malformations (e.g., corpus callosum and cerebellar vermis anomalies) reflecting early neurodevelopmental effects. rarediseases.info.nih.gov

12. Cerebral cortical atrophy—progressive loss in certain cortical areas contributing to cognitive and motor features. rarediseases.info.nih.gov

13. Lens development defects causing congenital/early cataracts, part of the RAB3GAP pathway spectrum. National Organization for Rare Disorders

14. Auditory pathway involvement leading to hearing impairment in some patients. rarediseases.info.nih.gov

15. Genetic background (modifiers)—other common variants may influence severity and age at onset (a general concept in HSP). PMC

16. Environmental stressors do not cause SPG69, but intercurrent illness or immobility can unmask or worsen spasticity symptoms. (General HSP care concept.) Cleveland Clinic

17. Consanguinity increases the chance that both parents carry the same rare recessive variant, raising risk in offspring (inheritance principle). rarediseases.info.nih.gov

18. Compound heterozygosity—two different damaging variants, one on each copy of RAB3GAP2, producing disease. (Typical recessive genetics.) genecards.org

19. Reduced or absent RAB3GAP2 expression (e.g., due to promoter/5′ variants) leading to too little functional protein. (Mechanistic extension consistent with gene function.) proteinatlas.org

20. Pathway cross-talk failure among vesicle trafficking, axonal transport, and synapse maintenance—tipping long motor tracts into dysfunction and spasticity. (HSP pathophysiology overview.) PMC+1

Symptoms

1. Leg stiffness (spasticity) – the muscles of the thighs and calves feel tight, making walking hard and causing a scissoring gait. Wikipedia

2. Leg weakness – over time the legs can feel heavy and weak, especially when climbing stairs or rising from a chair. Wikipedia

3. Overactive reflexes (hyperreflexia) – knee and ankle jerks are brisk when tested with a reflex hammer. Wikipedia

4. Clonus – rapid rhythmic jerks at the ankle when the foot is quickly stretched, due to the pathway injury in the spinal cord. rarediseases.info.nih.gov

5. Extensor plantar response (Babinski sign) – the big toe goes up when the sole is stroked, a sign of upper motor neuron damage. rarediseases.info.nih.gov

6. Delayed milestones / global developmental delay – late sitting, standing, walking, and slower speech and learning. rarediseases.info.nih.gov

7. Speech difficulty (dysarthria) – words can sound slurred because muscles that control speech are stiff or weak. rarediseases.info.nih.gov

8. Learning difficulties / intellectual disability – thinking and problem-solving may be below age expectations in some children. rarediseases.info.nih.gov

9. Cataracts – clouding of the eye lens, often early, which can blur vision and may need surgery. rarediseases.info.nih.gov

10. Hearing impairment – some children need hearing tests and support (hearing aids or other interventions). rarediseases.info.nih.gov

11. Abnormal eye movements / visual tracking issues – due to both lens changes and brain pathway involvement. National Organization for Rare Disorders

12. Poor balance or coordination – sometimes linked to changes in the cerebellar vermis seen on MRI. rarediseases.info.nih.gov

13. Thin or small connective pathways in the brain (corpus callosum agenesis/hypogenesis) – can relate to learning and motor planning challenges. rarediseases.info.nih.gov

14. Cortical atrophy on imaging – gradual loss of brain tissue in certain areas, which may relate to cognitive symptoms. rarediseases.info.nih.gov

15. Fatigue with walking – walking can take more effort because stiff muscles tire easily; rest and therapy help. (General HSP experience.) Cleveland Clinic

Symptom mix and severity vary by person—even in the same family. Most features of SPG69 begin in infancy/early childhood. rarediseases.info.nih.gov

---

Diagnostic tests

Goal: confirm the clinical picture of complex HSP, look for hallmark signs on exam, and prove the genetic cause (RAB3GAP2). The list covers bedside assessments, targeted manual scales, lab/genetic tests, neurophysiology, and imaging.

A) Physical examination

1. Full neurological exam – checks strength, tone, reflexes, plantar responses, and sensation; HSP shows spastic paraparesis with brisk reflexes and Babinski signs. PMC

2. Gait analysis in clinic – looks for scissoring gait, reduced foot clearance, toe drag, and balance issues typical of spasticity. PMC

3. Cranial nerve/eye exam – screens for cataracts, tracking, and visual fields; lens opacity suggests the RAB3GAP2 spectrum. rarediseases.info.nih.gov

4. Hearing screen (bedside/otoacoustic) – quick check prompting formal audiology if abnormal. rarediseases.info.nih.gov

5. Developmental assessment – age-appropriate testing of language, motor, and social skills to document global developmental delay. rarediseases.info.nih.gov

B) Manual/functional tests

6. Modified Ashworth Scale – standardized scale to grade muscle spasticity and track change over time. (Common HSP practice.) Cleveland Clinic

7. Timed Up and Go (TUG) – measures how long it takes to stand, walk 3 meters, turn, and sit; sensitive to spastic gait. (General HSP outcome.) sp-foundation.org

8. 10-Meter Walk Test – captures walking speed; slower speeds reflect functional impact of spasticity and weakness. (General HSP outcome.) sp-foundation.org

9. Spasticity triggers check (e.g., passive stretch tests) – bedside maneuvers to observe clonus and catch points. PMC

10. Gross Motor Function Measure (GMFM) or similar pediatric scales – structured measures for children to quantify motor skills over time. (General pediatric neuro practice for complex HSP.) Cleveland Clinic

C) Laboratory & pathological / genetic tests

11. Targeted single-gene testing of RAB3GAP2 – Sanger or NGS for sequence variants; confirms diagnosis when clinical suspicion is high. ensembl.org+1

12. HSP gene panel (NGS) – covers dozens of HSP genes at once; helpful because HSPs are genetically diverse. ResearchGate

13. Exome or genome sequencing (± CNV calling) – detects rare/novel variants and structural changes if panel is negative. (Standard rare-disease workflow.) ResearchGate

14. Copy-number analysis (exome-CNV/panel-CNV) – looks for exon-level deletions/duplications in RAB3GAP2. Eurofins Biomnis Connect

15. Segregation testing in parents – confirms autosomal recessive inheritance (each parent carries one variant). rarediseases.info.nih.gov

16. Basic metabolic labs (to rule out mimics) – while not diagnostic for SPG69, labs help exclude treatable look-alikes (e.g., B12 deficiency, thyroid disorders) per general HSP work-ups. medlink.com

D) Electrodiagnostic tests

17. Nerve-conduction studies (NCS) and electromyography (EMG) – check for peripheral neuropathy or coexisting motor unit problems; HSP is central, but tests refine the picture in complex cases. PMC

18. Evoked potentials (e.g., motor evoked potentials) – can show slowed central motor conduction consistent with corticospinal tract dysfunction. (Used in HSP assessments.) PMC

E) Imaging tests

19. Brain MRI – in SPG69 may show agenesis/hypogenesis of the corpus callosum, cerebellar vermis hypoplasia/aplasia, and cortical atrophy; these support a complex HSP pattern in the RAB3GAP2 spectrum. rarediseases.info.nih.gov

20. Spinal MRI – sometimes assesses for cord thinning or alternative causes of spasticity; mainly to exclude other pathologies. (General HSP imaging strategy.) PMC

Non-pharmacological treatments

1. Physiotherapy gait training
   Description: Regular supervised walking practice using treadmills, parallel bars, and real-world paths, often with cues and metronomes. Purpose: Improve walking speed, stride length, and endurance while reducing falls. Mechanism: Repetitive, task-specific practice drives motor learning and strengthens spared descending pathways; stretching between sets lowers reflex overactivity. Cleveland Clinic

2. Daily stretching program
   Description: Slow, sustained calf, hamstring, hip flexor, and adductor stretches (e.g., 30–60 seconds, multiple reps). Purpose: Reduce stiffness, prevent contractures, and ease pain. Mechanism: Prolonged stretch reduces muscle spindle excitability and keeps connective tissue length; consistent dosing preserves joint range in spastic conditions. Cleveland Clinic

3. Strength and conditioning
   Description: Progressive resistance for hip extensors, abductors, knee flexors/extensors, and core, 2–3 days/week. Purpose: Offset disuse weakness and improve transfers and stair skills. Mechanism: Hypertrophy and neural recruitment improve force generation around spastic groups, supporting more symmetric gait. Cleveland Clinic

4. Balance and fall-prevention therapy
   Description: Static/dynamic balance drills, obstacle negotiation, dual-task practice, and fall-recovery strategies. Purpose: Fewer falls and injuries; more confidence. Mechanism: Repeated exposure improves sensory re-weighting and anticipatory postural adjustments impaired by spasticity. Cleveland Clinic

5. Aquatic therapy
   Description: Pool-based gait, stretching, and balance using buoyancy and warm water. Purpose: Low-load strengthening with less fear of falling. Mechanism: Buoyancy unloads joints; warmth reduces stretch reflexes; hydrostatic pressure aids postural control. Cleveland Clinic

6. Functional electrical stimulation (FES)
   Description: Electrical pulses to dorsiflexors/plantarflexors during gait. Purpose: Improve foot clearance and push-off. Mechanism: Timed stimulation substitutes for weak or spastic activation and promotes neuroplasticity with repeated patterned use. Cleveland Clinic

7. Orthotics (AFOs) and footwear mods
   Description: Ankle–foot orthoses, wedges, rocker soles. Purpose: Better toe clearance, stance stability, and energy efficiency. Mechanism: External alignment limits pathologic plantarflexion/inversion and reduces spastic triggers during swing/stance. Cleveland Clinic

8. Serial casting/splinting
   Description: Short cycles of progressive casts or night splints. Purpose: Gain length in tight muscles and delay surgery. Mechanism: Prolonged low-load stretch remodels muscle–tendon and decreases reflex hyperexcitability. Cleveland Clinic

9. Occupational therapy for ADLs
   Description: Training for dressing, bathing, kitchen tasks, and workplace modifications. Purpose: Independence and safety. Mechanism: Task analysis plus adaptive tools reduces spasticity triggers and compensates for weakness/stiffness. Cleveland Clinic

10. Assistive mobility devices
    Description: Canes, forearm crutches, rollators, wheelchairs/scooters for distance. Purpose: Maintain community mobility and participation. Mechanism: Off-loading and stability reduce energy cost and fall risk in spastic gait. Cleveland Clinic

11. Body-weight supported treadmill training
    Description: Harness unloading while practicing stepping. Purpose: Build endurance and stepping symmetry. Mechanism: Central pattern generator engagement with reduced antigravity demand improves rhythmicity despite corticospinal injury. Cleveland Clinic

12. Bladder training and timed voiding
    Description: Schedules, urge-suppression, pelvic floor strategies. Purpose: Fewer accidents and urgency. Mechanism: Behavioral retraining modulates detrusor overactivity and strengthens pelvic floor synergy. Cleveland Clinic

13. Bowel program
    Description: Scheduled toileting, fiber/fluids, abdominal massage, and suppository routines. Purpose: Reduce constipation and incontinence. Mechanism: Regular habits and stool softening lower reflex spasm triggers and straining. Cleveland Clinic

14. Speech and swallow therapy (if involved)
    Description: Strategies for dysarthria or dysphagia in “complicated” phenotypes. Purpose: Safer eating, clearer speech. Mechanism: Targeted oromotor drills and compensations reduce aspiration risk. Cleveland Clinic

15. Home safety and environmental changes
    Description: Remove trip hazards, add rails, improve lighting, install ramps. Purpose: Prevent falls at home. Mechanism: Environmental control reduces balance demands during daily mobility. Cleveland Clinic

16. Pain self-management (heat/cold, pacing)
    Description: Warm packs, gentle massage, activity pacing. Purpose: Ease muscle pain from overuse and stiffness. Mechanism: Temperature and pacing reduce nociceptive input and spasm triggers. Cleveland Clinic

17. Mind–body practice (yoga/Tai Chi/mindfulness)
    Description: Slow, guided movements and breathing. Purpose: Lower anxiety and muscle tone. Mechanism: Autonomic calming reduces sympathetic drive contributing to spasticity. Cleveland Clinic

18. TENS for focal discomfort
    Description: Transcutaneous stimulation near painful muscles. Purpose: Short-term pain relief to allow exercise. Mechanism: Gate-control analgesia reduces pain signal transmission. Cleveland Clinic

19. Community exercise and fatigue management
    Description: Graded walking/cycling with rest plans. Purpose: Sustain activity safely. Mechanism: Aerobic conditioning improves efficiency and reduces perceived exertion in spastic gait. Cleveland Clinic

20. Genetic counseling for families
    Description: Education on inheritance, testing options, and family planning. Purpose: Informed choices and early support. Mechanism: Clarifies autosomal recessive risks and directs testing to the causative gene. Cleveland Clinic+1

---

Drug treatments

Important: SPG69 has no drug that reverses the gene defect. Medicines below target spasticity, bladder overactivity, neuropathic pain, drooling, mood, sleep, etc. Always individualize dosing with your clinician.

1. Baclofen (oral) – GABA-B agonist; antispasticity.
   Class: Central muscle relaxant. Typical dose/time: Start 5 mg 3×/day, titrate (common max 80 mg/day). Purpose: Lower leg stiffness, improve ease of walking and stretching. Mechanism: Stimulates spinal GABA-B receptors, reducing excitatory neurotransmission to alpha motor neurons, lowering spastic reflexes. Side effects: Drowsiness, dizziness, weakness; abrupt stop can cause withdrawal (rare seizures/hyperthermia). Evidence: FDA labeling recognizes baclofen for spasticity (not disease-specific to HSP). malacards.org

2. Baclofen (intrathecal; Lioresal® Intrathecal) – for severe refractory spasticity
   Class: GABA-B agonist delivered via pump. Dose/time: Test dose via lumbar puncture; if responsive, implant pump with continuous infusion, titrated by specialist. Purpose: Control severe spasticity with fewer systemic effects than high-dose oral therapy. Mechanism: Direct spinal delivery increases local GABAergic tone. Side effects: Pump/catheter complications, overdose/withdrawal risks; monitoring essential. Evidence: FDA labeling for severe spasticity of cerebral or spinal origin. Neurology

3. Tizanidine
   Class: α2-adrenergic agonist (central). Dose/time: Often 2–4 mg up to 3×/day, carefully titrated. Purpose: Reduce tone and spasms. Mechanism: Presynaptic inhibition of motor interneurons. Side effects: Sedation, dry mouth, hypotension, liver enzyme elevations—monitor LFTs. Evidence: FDA label for spasticity. Orpha

4. Dantrolene
   Class: Direct-acting muscle relaxant on skeletal muscle. Dose/time: Oral capsules titrated (e.g., 25–100 mg up to QID in labels for spasticity); IV form for malignant hyperthermia. Purpose: Reduce spasticity when centrally acting agents fail or cause sedation. Mechanism: Lowers calcium release from sarcoplasmic reticulum (RYR1), weakening excessive contraction. Side effects: Hepatotoxicity risk (monitor), weakness, GI upset. Evidence: FDA labeling details spasticity use. FDA Access Data

5. OnabotulinumtoxinA (BOTOX®) – focal spasticity
   Class: Botulinum toxin type A. Dose/time: Injected into overactive muscles every ~12 weeks. Purpose: Relax focal problem muscles (e.g., calves, hip adductors) to improve gait or brace fit. Mechanism: Blocks acetylcholine release at neuromuscular junction. Side effects: Local weakness, pain; rare distant spread effects. Evidence: FDA labeling for adult spasticity. Open Access Government

6. AbobotulinumtoxinA (Dysport®) – focal spasticity
   Class: Botulinum toxin type A. Dose/time: Administered by trained injectors, repeat ~12–16 weeks. Purpose/Mechanism/Side effects: As above. Evidence: FDA labeling includes adult upper/lower limb spasticity. PMC

7. IncobotulinumtoxinA (Xeomin®) – focal spasticity
   Class: Botulinum toxin type A (without complexing proteins). Dose/time: Tailored dosing by muscle size/pattern. Purpose: Alternative BoNT-A with similar effects. Mechanism/Side effects: Same class effects. Evidence: FDA labeling for spasticity. FDA Access Data

8. RimabotulinumtoxinB (Myobloc®) – when BoNT-A is insufficient or not tolerated
   Class: Botulinum toxin type B. Dose/time: Specialist-guided injection cycles. Purpose: Focal tone control (e.g., adductors); also approved for cervical dystonia. Mechanism: Blocks acetylcholine via synaptobrevin cleavage. Side effects: Dry mouth, weakness. Evidence: FDA labeling. ScienceDirect

9. Diazepam (Valium®) – adjunct for spasms/night spasms
   Class: Benzodiazepine (GABA-A positive modulator). Dose/time: Low dose at night or divided; caution with CNS depressants. Purpose: Short-term relief of spasms and anxiety that worsens tone. Mechanism: Enhances GABA-A inhibition. Side effects: Sedation, dependence, respiratory depression with opioids—boxed warnings. Evidence: FDA labeling includes relief of skeletal muscle spasm. FDA Access Data

10. Gabapentin (Neurontin®) – neuropathic pain
    Class: α2δ calcium-channel ligand. Dose/time: Titrate (commonly 900–1800 mg/day in divided doses). Purpose: Treat burning, tingling, neuropathic pain sometimes seen with HSP. Mechanism: Reduces excitatory neurotransmitter release. Side effects: Dizziness, somnolence; rare breathing risk with CNS depressants. Evidence: FDA labeling for neuropathic pain and seizure adjunct. FDA Access Data

11. Pregabalin (Lyrica® / Lyrica CR®) – neuropathic pain
    Class: α2δ ligand. Dose/time: Typical 150–300 mg/day (max per label varies; adjust for kidneys). Purpose: Reduce neuropathic pain, improve sleep. Mechanism: Reduces calcium-dependent neurotransmission. Side effects: Edema, weight gain, dizziness; controlled substance (C-V). Evidence: FDA labeling. FDA Access Data

12. Oxybutynin ER (Ditropan XL®) – overactive bladder/urgency
    Class: Antimuscarinic. Dose/time: Often 5–10 mg once daily ER. Purpose: Reduce urgency, frequency, leakage. Mechanism: M3 receptor blockade reduces detrusor overactivity. Side effects: Dry mouth, constipation, blurred vision, confusion in sensitive patients. Evidence: FDA labeling for OAB. FDA Access Data

13. Tolterodine (Detrol LA®) – overactive bladder
    Class: Antimuscarinic. Dose/time: 2–4 mg once daily LA. Purpose/Mechanism: Similar to oxybutynin; sometimes better tolerated. Side effects: Anticholinergic effects; adjust in hepatic/renal impairment. Evidence: FDA labeling. FDA Access Data

14. Solifenacin (Vesicare®) – overactive bladder
    Class: Antimuscarinic. Dose/time: 5 mg daily, may increase to 10 mg if tolerated. Purpose: Control urgency/incontinence. Mechanism: M3 antagonism. Side effects: Dry mouth, constipation; dose limits with CYP3A4 inhibitors or liver disease. Evidence: FDA labeling. FDA Access Data

15. Mirabegron (Myrbetriq®) – overactive bladder alternative or add-on
    Class: β3-adrenergic agonist. Dose/time: Label-guided dosing (e.g., 25–50 mg daily; pediatric granules exist). Purpose: Reduce urgency/frequency, often combined with solifenacin if needed. Mechanism: Relaxes detrusor muscle during storage. Side effects: Can raise blood pressure; CYP2D6 interactions. Evidence: FDA labeling. FDA Access Data

16. Glycopyrrolate (Cuvposa® oral solution) – pathologic drooling (sialorrhea)
    Class: Anticholinergic. Dose/time: Weight-based titration in children; adults sometimes use off-label tablets—specialist guidance. Purpose: Reduce saliva pooling and skin breakdown. Mechanism: Blocks muscarinic receptors in salivary glands. Side effects: Dry mouth, constipation, urinary retention, blurred vision. Evidence: FDA labeling for pediatric neurologic sialorrhea. FDA Access Data

17. Atropine (ophthalmic 1%) – caution if used off-label for drooling
    Class: Antimuscarinic. Dose/time: Label is ophthalmic; sublingual use is off-label and carries toxicity risks. Purpose: Sometimes tried for sialorrhea under specialist care. Mechanism: Reduces salivary secretion. Side effects: Significant anticholinergic and cardiovascular risks if systemically absorbed—use extreme caution. Evidence: FDA labeling is ophthalmic; literature documents overdose risk with off-label sublingual use. FDA Access Data+1

18. Sertraline (Zoloft®) – depression/anxiety common in chronic neurologic disease
    Class: SSRI. Dose/time: Start low (e.g., 25–50 mg daily), titrate. Purpose: Improve mood, coping, adherence to rehab. Mechanism: Inhibits serotonin reuptake. Side effects: GI upset, insomnia/activation, sexual dysfunction; boxed warning for suicidality in youth. Evidence: FDA labeling. FDA Access Data

19. RimabotulinumtoxinB for drooling (select cases)
    Class: BoNT-B. Dose/time: Injected to salivary glands when drooling persists; specialist-guided. Purpose: Reduce sialorrhea. Mechanism: Blocks acetylcholine at parasympathetic terminals. Side effects: Dry mouth, swallowing difficulty if overdosed. Evidence: FDA labeling supports BoNT-B use (primary indication cervical dystonia; sialorrhea labeling may vary by product—confirm locally). ScienceDirect

20. Multimodal bowel medications (when needed)
    Class: Per clinical need (e.g., stool softeners, osmotics). Purpose: Manage constipation that worsens spasticity and discomfort. Mechanism/Side effects: Increase stool water or motility; specific labels vary. Evidence: Use per FDA-approved labeling of individual products and clinician guidance. (General supportive statement; choose product-specific FDA labeling when prescribing.) Cleveland Clinic

---

Dietary molecular supplements

1. Vitamin D3
   Description: Supports bone/muscle function; deficiency is common and worsens falls. Dose: Often 800–2000 IU/day (adjust to levels). Function/Mechanism: Vitamin D receptors in muscle aid calcium handling and strength; correcting deficiency improves balance and reduces fall risk in many populations. Evidence: NIH Office of Dietary Supplements and clinical reviews highlight musculoskeletal roles; check 25-OH vitamin D before dosing. monarchinitiative.org

2. Omega-3 (EPA/DHA)
   Description: Anti-inflammatory fatty acids from fish oil. Dose: Commonly 1–2 g/day total EPA+DHA. Function/Mechanism: Modulate eicosanoids and membrane fluidity, which may support nerve health and reduce low-grade inflammation contributing to pain. Evidence: Reviews describe neuroprotective and anti-inflammatory effects; benefits are modest and patient-specific. PubMed

3. Vitamin B12
   Description: Essential for myelin and DNA synthesis. Dose: 500–1000 µg/day oral or as prescribed if deficient. Function/Mechanism: Correcting deficiency treats neuropathy-like symptoms that can mimic or worsen gait issues. Evidence: NIH ODS notes neurologic consequences of deficiency; test levels before supplementation. ClinicalTrials.gov

4. Magnesium
   Description: Muscle/nerve cofactor that may reduce cramps. Dose: 200–400 mg/day (elemental), adjusted for kidneys. Function/Mechanism: Competes with calcium at neuromuscular junction and may blunt hyperexcitability. Evidence: Trials show mixed results for cramps; benefit is individualized. Orpha

5. Coenzyme Q10 (CoQ10)
   Description: Mitochondrial cofactor supporting energy production. Dose: 100–300 mg/day. Function/Mechanism: Improves electron transport chain efficiency; may reduce fatigue perceptions. Evidence: Reviews in neurological disorders show variable benefits; generally well tolerated. JAMA Network

6. Creatine Monohydrate
   Description: Energy buffer that supports short-burst muscle work. Dose: 3–5 g/day (no loading needed). Function/Mechanism: Increases phosphocreatine stores for repeated contractions; may assist strength training. Evidence: Systematic reviews in neuromuscular conditions show mixed but safe profiles. malacards.org

7. Alpha-lipoic acid
   Description: Antioxidant used in diabetic neuropathy. Dose: 300–600 mg/day. Function/Mechanism: Scavenges reactive oxygen species; may improve nerve blood flow. Evidence: RCTs in neuropathy report symptom relief; specific HSP data are lacking. Neurology

8. L-carnitine (acetyl-L-carnitine)
   Description: Shuttles fatty acids into mitochondria. Dose: 500–1000 mg 1–2×/day. Function/Mechanism: Supports energy metabolism and may reduce neuropathic discomfort. Evidence: Reviews suggest benefit in some neuropathic states; can cause GI upset. FDA Access Data

9. Curcumin
   Description: Anti-inflammatory polyphenol from turmeric. Dose: Standardized extracts per label. Function/Mechanism: NF-κB modulation may reduce low-grade inflammation and soreness after therapy sessions. Evidence: Broad anti-inflammatory literature; disease-specific data limited. Cleveland Clinic

10. Resveratrol
    Description: Polyphenol with antioxidant signaling effects. Dose: Various (e.g., 150–500 mg/day in supplements). Function/Mechanism: Activates sirtuin pathways; theoretical neuroprotective effects. Evidence: Preclinical/early clinical data only; discuss risks/benefits. PMC

---

Immunity-booster / Regenerative / Stem-cell” drugs

1. Stem-cell therapies (MSC or other cell infusions)
   Description: Marketed in some clinics, but no FDA-approved stem-cell products for SPG69/HSP. Mechanism aims at neurorepair or anti-inflammation. Reality: Evidence is investigational; risks include infection, immune reactions, and cost. Regulatory caution: FDA warns against unapproved stem-cell products outside clinical trials. U.S. Food and Drug Administration

2. Gene therapy (overall concept)
   Description: For some HSP subtypes, early-stage programs explore gene replacement/silencing. For SPG69 (RAB3GAP2), no approved therapy yet; research is evolving for HSP more broadly. Patients may qualify for natural-history or exploratory studies. PMC

3. Neurotrophic-pathway drugs (experimental classes)
   Description: Agents that upregulate growth factors or axonal transport are being studied in related motor disorders. None is approved for HSP; participation is via trials only. PMC

4. Immune-modulators (general note)
   Description: HSP is not primarily autoimmune; routine “immune-boosters” or immunosuppressants are not standard. Use only if a comorbid autoimmune disorder exists, under specialist care. PMC

5. High-dose antioxidants “neuro-repair” cocktails
   Description: Sold online; claims exceed evidence. Potential for drug interactions and GI side effects. Discuss with your physician and prioritize exercise/therapy first. PMC

6. Platelet-rich plasma or biologics injected near nerves
   Description: Promoted in some centers but not approved for HSP spasticity. Avoid outside trials. U.S. Food and Drug Administration

---

Surgeries and procedures

1. Intrathecal baclofen pump implantation
   Procedure: Test dose; if effective, small pump placed under abdomen with catheter to spinal fluid. Why: Continuous baclofen delivery for severe, generalized spasticity unresponsive to pills/injections, improving comfort and care. Neurology

2. Botulinum toxin guided chemodenervation
   Procedure: Needle injections into overactive muscles using EMG/ultrasound guidance, repeated every few months. Why: Target focal spasticity (e.g., calves, adductors) that causes toe-walking, scissoring, or brace problems. Open Access Government

3. Orthopedic soft-tissue lengthening
   Procedure: Lengthening of Achilles/hamstrings/adductors when fixed contractures limit walking or hygiene. Why: Restore joint range, improve brace fit, and relieve pain when conservative care fails. PMC

4. Orthopedic bony procedures / foot deformity correction
   Procedure: Osteotomies or fusions to correct severe foot/ankle malalignment. Why: Stabilize stance, fit shoes/orthoses, and reduce ulcer risk. PMC

5. Urologic procedures (selected cases)
   Procedure: Botulinum toxin injections to detrusor or other interventions for refractory overactive bladder. Why: Reduce urgency, leakage, and infections when medicines/behavioral care are inadequate. FDA Access Data

---

Preventions

1. Daily stretching to prevent contractures and pain. Cleveland Clinic

2. Regular strength and balance training to reduce falls. Cleveland Clinic

3. Home safety changes (rails, remove rugs) to prevent injuries. Cleveland Clinic

4. Use the right orthotics/footwear to avoid trips and skin sores. Cleveland Clinic

5. Stay hydrated and fiber-adequate to prevent constipation flare-ups. Cleveland Clinic

6. Bladder training to cut urgency and accidents. Cleveland Clinic

7. Vaccinations and infection control (UTIs worsen spasticity). Cleveland Clinic

8. Medication review to avoid sedatives that increase falls. FDA Access Data

9. Sunlight/Vitamin D adequacy to reduce fractures from falls. monarchinitiative.org

10. Genetic counseling for family planning. Mayo Clinic Laboratories

---

When to see doctors

See a neurologist/physiatrist early if you or your child has progressive leg stiffness, toe-walking, scissoring gait, or frequent falls. Seek care urgently for rapid weakness, new bladder retention, fever with severe spasms, pump alarm (if implanted), or painful red calf suggesting DVT. Ask for genetic testing if HSP is suspected—multigene panels or exome identify many HSP genes including RAB3GAP2 (SPG69) and help tailor family counseling. Follow-ups should review spasticity, mobility aids, bladder/bowel plans, skin care, mood, and fall risk. Cleveland Clinic+1

---

What to eat” and “what to avoid”

Eat:

1. High-fiber foods (whole grains, legumes, veg) to prevent constipation that worsens spasms. Cleveland Clinic

2. Protein with each meal to support muscle maintenance during therapy. Cleveland Clinic

3. Hydration (water) to reduce UTIs and stool hardening. Cleveland Clinic

4. Calcium + vitamin D-rich foods for bone strength with fall risk. monarchinitiative.org

5. Omega-3 sources (fatty fish, walnuts) for general anti-inflammatory support. PubMed

Avoid/limit:

1. Excess alcohol—worsens balance and interacts with medicines (e.g., benzodiazepines, pregabalin). FDA Access Data
2. High-sugar drinks/snacks—weight gain raises mobility effort. Cleveland Clinic
3. Very salty foods—fluid shifts can worsen BP (important with mirabegron). FDA Access Data
4. Caffeine late day—may raise urgency and disturb sleep. Cleveland Clini
5. Unregulated supplements—risk of interactions and false “cure” claims; verify labels and evidence. U.S. Food and Drug Administratio

---

Frequently Asked Questions

1. Is SPG69 curable?
   Not yet. Care focuses on spasticity control, mobility, bladder/bowel health, mood, and safety, guided by genetic confirmation when possible. Cleveland Clinic+1

2. What gene causes SPG69?
   RAB3GAP2 variants, an alias recorded as SPG69 in gene catalogs. Wikipedia

3. How is SPG69 diagnosed?
   By symptoms/exam plus genetic testing panels/exome that include RAB3GAP2. Mayo Clinic Laboratories

4. What is “pure” vs “complicated” HSP?
   Pure = mainly leg spasticity/weakness; complicated = added features (e.g., eye, cognitive, peripheral nerve). SPG69 can vary. Cleveland Clinic

5. Why do legs feel stiff and weak together?
   Spasticity over-activates reflexes while long tracts degenerate, causing both stiffness and true weakness. Cleveland Clinic

6. Will exercise make me worse?
   No—proper, paced exercise helps strength, balance, and flexibility. Avoid over-fatigue and follow a therapist’s plan. Cleveland Clinic

7. Are there medicines to loosen muscles?
   Yes (baclofen, tizanidine, dantrolene, botulinum toxins), chosen to match your pattern and side-effect profile. Orpha+2FDA Access Data+2

8. What if pills make me too sleepy?
   Options include focal botulinum injections or intrathecal baclofen to reduce systemic effects. Open Access Government+1

9. Can bladder urgency improve?
   Yes—behavioral training plus medications like oxybutynin, tolterodine, solifenacin, mirabegron. FDA Access Data+3FDA Access Data+3FDA Access Data+3

10. Are “stem-cell cures” real for SPG69 now?
    No approved stem-cell treatments for HSP; FDA advises caution outside clinical trials. U.S. Food and Drug Administration

11. Do I need regular MRIs?
    Usually at diagnosis to exclude mimics; later scans only if new symptoms suggest other issues. Cleveland Clinic

12. Should my family be tested?
    Genetic counseling helps decide targeted testing for relatives because SPG69 is autosomal recessive. Mayo Clinic Laboratories

13. Can diet help?
    Diet cannot cure HSP but supports bowel/bladder health, bones, and training tolerance (fiber, fluids, calcium/vitamin D, omega-3s). monarchinitiative.org+1

14. What about vitamins and supplements?
    Use to correct deficiencies (e.g., vitamin D, B12). Others have mixed evidence; discuss dosing and interactions with your clinician. monarchinitiative.org+1

15. Where can I learn more about management?
    Neuromuscular clinics and reputable centers outline HSP testing/treatment basics and rehab options. Cleveland Clinic

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 13, 2025.